GO:0046975 histone H3K36 methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046975 describes the enzymatic activity that transfers a methyl group from S-adenosyl-L-methionine to lysine 36 of histone H3, producing S-adenosyl-L-homocysteine and H3K36me.
• Major human enzymes with this activity include SETD2, NSD1, NSD2, NSD3, and ASH1L, which differ in product specificity and biological context.
• H3K36 methylation is linked to transcriptional elongation, enhancer regulation, and cell-fate control, and its dysregulation is observed in cancer, osteoarthritis, and developmental disorders.
• Disease-associated mutations, such as SETD2 L1609P in leukemia and NSD3 alterations in squamous cell lung cancer, can disrupt methyltransferase activity and reduce H3K36 trimethylation.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal testing of H3K36 methyltransferase genes in relevant cell types.
• Integrating chromatin assays, transcriptomics, and proteomics helps define how H3K36 methylation states control gene expression and cellular phenotypes.
Description
Histone H3K36 methyltransferase activity (GO:0046975) is a molecular function that catalyzes the transfer of a methyl group to lysine 36 of histone H3 using S-adenosyl-L-methionine as the methyl donor. This modification, referred to as H3K36 methylation, occurs in mono-, di-, and trimethylated forms and is deposited by SET-domain-containing enzymes such as SETD2, NSD1, NSD2, NSD3, and ASH1L. Because H3K36 methylation is associated with active transcription and chromatin regulation, its precise control is important for normal development and tissue homeostasis. Researchers study GO:0046975 to understand how epigenetic marks are written, how they influence gene expression programs, and how their disruption contributes to disease. For example, elevated NSD3 histone methylation activity drives squamous cell lung cancer, and NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis. In addition, NSD1 protects against osteoarthritis by regulating chondrocyte differentiation and cartilage homeostasis, and the Sotos syndrome gene NSD1 controls transcriptional enhancers and cell fate. These findings highlight the broad relevance of H3K36 methyltransferase activity across cancer, skeletal disease, and developmental disorders. This article provides a research-grade overview of GO:0046975, covering its definition, catalytic mechanism, key genes, disease connections, and experimental strategies. It is intended for scientists who need a concise, citable resource for grant writing, experimental design, and interpretation of epigenetic data.
histone H3K36 methyltransferase activity At A Glance
| GO ID | GO:0046975 |
|---|---|
| GO term | histone H3K36 methyltransferase activity |
| Ontology | molecular_function |
| Synonym | histone H3K36 methylase activity; histone-H3K36 methyltransferase activity; histone lysine N-methyltransferase activity (H3-K36 specific); histone methylase activity (H3-K36 specific); histone methyltransferase activity (H3-K36 specific) |
| Major function | Transfer of a methyl group from S-adenosyl-L-methionine to histone H3 lysine 36, producing S-adenosyl-L-homocysteine and H3K36 methylated histone H3 |
| Reaction | S-adenosyl-L-methionine + histone H3 L-lysine (position 36) = S-adenosyl-L-homocysteine + histone H3 N6-methyl-L-lysine (position 36) |
| Cofactor | S-adenosyl-L-methionine as methyl donor |
| Product | H3K36me1, H3K36me2, and H3K36me3, depending on enzyme and context |
| Representative enzymes | SETD2, NSD1, NSD2, NSD3, ASH1L |
What Is GO:0046975?
GO:0046975, histone H3K36 methyltransferase activity, is defined as the catalysis of the reaction: S-adenosyl-L-methionine + histone H3 L-lysine at position 36 = S-adenosyl-L-homocysteine + histone H3 N6-methyl-L-lysine at position 36. In other words, it is the enzymatic addition of a methyl group to the lysine residue at position 36 of the histone H3 protein.
Why Is histone H3K36 methyltransferase activity Important in Cell Biology?
Histone H3K36 methyltransferase activity is important because it establishes a chromatin mark that influences transcription, cell identity, and genome stability. Dysregulation of this activity is observed in multiple cancers, including squamous cell lung cancer and lung adenocarcinoma, and in non-malignant conditions such as osteoarthritis and Sotos syndrome. Understanding GO:0046975 therefore provides mechanistic insight into epigenetic control and identifies potential targets for therapeutic intervention.
• H3K36 methylation is a key epigenetic mark associated with active transcription and chromatin regulation.
• Enzymes with this activity, such as SETD2, NSD1, NSD2, and NSD3, are frequently altered in human cancers.
• NSD3 histone methylation activity drives squamous cell lung cancer, highlighting a direct oncogenic role.
• NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis.
• NSD1 protects against osteoarthritis by regulating chondrocyte differentiation and cartilage homeostasis.
• NSD1, the Sotos syndrome gene, regulates transcriptional enhancers and cell fate.
• SETD2 mutations, such as L1609P in leukemia, can disrupt methyltransferase activity and reduce H3K36 trimethylation.
• Caf1 regulates the histone methyltransferase activity of Ash1 by sensing unmodified histone H3, illustrating layered regulation.
• Epigenetic therapies targeting histone lysine methylation are under investigation but face complex mechanisms and clinical challenges.
• CRISPR-based models enable causal testing of H3K36 methyltransferase genes in disease-relevant contexts.
What Happens During histone H3K36 methyltransferase activity?
Substrate recognition and binding
In simple terms: The enzyme first finds and binds to histone H3, the protein that DNA wraps around.
H3K36 methyltransferases recognize the histone H3 tail, often in the context of nucleosomes and actively transcribed chromatin. Structural and biochemical studies show that SETD2 engages H3K36 during chromatin transcription, positioning the target lysine for methyl transfer. Caf1 regulates the histone methyltransferase activity of Ash1 by sensing unmodified histone H3, indicating that substrate recognition can be modulated by accessory factors.
Methyl group transfer
In simple terms: The enzyme takes a methyl group from a donor molecule and attaches it to lysine 36 of histone H3.
The catalytic reaction uses S-adenosyl-L-methionine as the methyl donor and produces S-adenosyl-L-homocysteine and methylated histone H3. Depending on the enzyme and context, the product can be mono-, di-, or trimethylated H3K36, with SETD2 notably catalyzing H3K36 trimethylation during transcription. NSD2 dimethylation at H3K36 is linked to lung adenocarcinoma pathogenesis, showing that product specificity matters for disease.
Product specificity and chromatin context
In simple terms: Different enzymes can add one, two, or three methyl groups, and the outcome depends on the surrounding chromatin.
H3K36 methylation states are distributed across gene bodies and are associated with transcriptional elongation and enhancer regulation. NSD1 regulates transcriptional enhancers and cell fate, and its activity is important for chondrocyte differentiation and cartilage homeostasis. Elevated NSD3 histone methylation activity drives squamous cell lung cancer, demonstrating that excess activity can be oncogenic.
Regulation by accessory proteins and mutations
In simple terms: Other proteins and genetic changes can turn the enzyme up or down.
Caf1 regulates the histone methyltransferase activity of Ash1 by sensing unmodified histone H3, providing an example of allosteric or cofactor-like control. Disease-associated mutations such as SETD2 L1609P in leukemia disrupt methyltransferase activity and reduce histone H3K36 trimethylation. These findings illustrate that both trans-acting regulators and cis mutations can alter GO:0046975 activity.
Key Genes Involved in GO:0046975 histone H3K36 methyltransferase activity
The following genes encode enzymes or regulators directly associated with histone H3K36 methyltransferase activity (GO:0046975) in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SETD2 | H3K36 trimethyltransferase during chromatin transcription | Structural basis of H3K36 trimethylation; leukemia-associated L1609P mutation disrupts activity |
| NSD1 | H3K36 methyltransferase regulating enhancers and cell fate | Protects against osteoarthritis; Sotos syndrome gene; regulates chondrocyte differentiation |
| NSD2 | H3K36 dimethyltransferase | Promotes lung adenocarcinoma pathogenesis |
| NSD3 | H3K36 methyltransferase with elevated activity in cancer | Drives squamous cell lung cancer |
| ASH1L | H3K36 methyltransferase regulated by Caf1 | Caf1 senses unmodified histone H3 to regulate Ash1 activity |
| Caf1 | Regulator of Ash1 histone methyltransferase activity | Senses unmodified histone H3 to control H3K36 methylation |
| H3-3A | Histone H3 variant substrate | Provides lysine 36 for methylation; relevant to chromatin assays |
| H3-3B | Histone H3 variant substrate | Provides lysine 36 for methylation; relevant to chromatin assays |
| H3C1 | Histone H3 substrate | Canonical substrate for H3K36 methyltransferases |
| H3C2 | Histone H3 substrate | Canonical substrate for H3K36 methyltransferases |
| H3C3 | Histone H3 substrate | Canonical substrate for H3K36 methyltransferases |
| H3C4 | Histone H3 substrate | Canonical substrate for H3K36 methyltransferases |
| H3C6 | Histone H3 substrate | Canonical substrate for H3K36 methyltransferases |
| H3C7 | Histone H3 substrate | Canonical substrate for H3K36 methyltransferases |
| H3C8 | Histone H3 substrate | Canonical substrate for H3K36 methyltransferases |
| H3C10 | Histone H3 substrate | Canonical substrate for H3K36 methyltransferases |
| H3C11 | Histone H3 substrate | Canonical substrate for H3K36 methyltransferases |
| H3C12 | Histone H3 substrate | Canonical substrate for H3K36 methyltransferases |
How Is histone H3K36 methyltransferase activity Regulated?
Histone H3K36 methyltransferase activity is regulated at multiple levels. Accessory proteins such as Caf1 can sense unmodified histone H3 and modulate the activity of Ash1, illustrating substrate-dependent regulation. Disease-associated mutations, such as SETD2 L1609P, can directly impair catalytic activity and reduce H3K36 trimethylation. In cancer, elevated NSD3 activity and NSD2-mediated H3K36 dimethylation demonstrate that expression levels and intrinsic activity of these enzymes are subject to dysregulation. Epigenetic therapies targeting histone lysine methylation are being explored, but the complex mechanisms and clinical challenges underscore the need for precise mechanistic understanding.
histone H3K36 methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NSD3 | Squamous cell lung cancer | Knockout or point-mutation in lung squamous cell lines; overexpression models |
| NSD2 | Lung adenocarcinoma | Knockout and overexpression in lung adenocarcinoma cell lines |
| SETD2 | Leukemia | Point-mutation knock-in of L1609P in leukemia cell lines |
| NSD1 | Osteoarthritis; Sotos syndrome | Knockout in chondrocytes; enhancer reporter assays |
| ASH1L | Chromatin regulation | Knockout and regulator (Caf1) perturbation in cell models |
Cancer
H3K36 methyltransferase activity is directly implicated in several cancers. Elevated NSD3 histone methylation activity drives squamous cell lung cancer, and NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis. SETD2 mutations, such as L1609P found in leukemia, disrupt methyltransferase activity and reduce histone H3K36 trimethylation, suggesting a tumor-suppressive role for SETD2 in some contexts. These findings position GO:0046975 as a potential therapeutic target and biomarker in oncology.
Osteoarthritis and skeletal disease
NSD1, an H3K36 methyltransferase, protects against osteoarthritis by regulating chondrocyte differentiation and cartilage homeostasis. This links GO:0046975 to non-malignant degenerative joint disease and suggests that modulating H3K36 methylation could influence cartilage maintenance.
Developmental disorders
NSD1 is the Sotos syndrome gene and regulates transcriptional enhancers and cell fate. Disruption of its H3K36 methyltransferase activity may contribute to developmental phenotypes through altered enhancer function and cell-fate decisions.
From histone H3K36 methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SETD2 reduce H3K36 trimethylation? | SETD2 knockout cell line |
| Does the SETD2 L1609P mutation impair methyltransferase activity? | Point-mutation knock-in of L1609P |
| Does NSD3 overexpression drive squamous cell lung cancer phenotypes? | NSD3 overexpression in lung squamous cell lines |
| Does NSD2 dimethylation at H3K36 promote lung adenocarcinoma? | NSD2 knockout and overexpression in lung adenocarcinoma cells |
| Does NSD1 regulate enhancers and chondrocyte differentiation? | NSD1 knockout in chondrocytes; enhancer reporter assays |
| How does Caf1 regulate Ash1 activity? | ASH1L and Caf1 perturbation models |
How to Study the histone H3K36 methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genome-wide distribution of H3K36 methylation | Mapping changes upon SETD2 or NSD1 perturbation |
| Western blot | Global levels of H3K36me1/2/3 | Validating loss of activity in mutant cells |
| RNA-seq | Transcriptional changes | Assessing impact on gene expression programs |
| ATAC-seq | Chromatin accessibility | Evaluating enhancer regulation by NSD1 |
| Co-immunoprecipitation / mass spectrometry | Protein-protein interactions | Identifying regulators such as Caf1 with Ash1 |
| Recombinant methyltransferase assay | Enzymatic activity and product specificity | Testing NSD3 or SETD2 activity in vitro |
| Structural biology (cryo-EM / crystallography) | Three-dimensional enzyme-substrate complexes | Understanding SETD2 catalysis during transcription |
| CRISPR screening | Functional dependencies | Identifying genes that modulate H3K36 methylation |
Chromatin immunoprecipitation and histone modification assays
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) or quantitative PCR can map H3K36 methylation states across the genome and assess changes upon perturbation of H3K36 methyltransferases. Western blotting with modification-specific antibodies can quantify global H3K36me1, H3K36me2, and H3K36me3 levels, as shown for SETD2 L1609P.
Transcriptomics and enhancer profiling
RNA-seq and enhancer-associated assays such as ATAC-seq or H3K27ac ChIP-seq can reveal how loss or gain of H3K36 methyltransferase activity affects gene expression programs and enhancer function. These approaches are particularly useful for studying NSD1-dependent enhancer regulation and cell-fate control.
Proteomics and interactomics
Affinity purification coupled with mass spectrometry can identify proteins that associate with H3K36 methyltransferases and regulate their activity, such as Caf1 with Ash1. Such studies help define the composition of enzyme complexes and potential cofactors.
Structural and biochemical assays
Recombinant enzyme assays using histone substrates and S-adenosyl-L-methionine can measure catalytic activity and product specificity. Structural studies, such as those of SETD2 during chromatin transcription, provide mechanistic insight into substrate recognition and catalysis.
How CRISPR Can Be Used to Study GO:0046975 histone H3K36 methyltransferase activity
Knockout
CRISPR knockout of H3K36 methyltransferase genes such as SETD2, NSD1, NSD2, NSD3, or ASH1L can abolish specific methylation marks and reveal their cellular functions. For example, NSD1 knockout models have been used to study chondrocyte differentiation and cartilage homeostasis.
Point Mutation
Point-mutation knock-in, such as SETD2 L1609P, allows precise testing of disease-associated variants for their effects on methyltransferase activity and H3K36 trimethylation. This approach is valuable for distinguishing loss-of-function from other mechanisms.
Knock-in
Knock-in of tagged or reporter alleles can facilitate tracking of H3K36 methyltransferase expression, localization, and interaction partners in live cells. Such models complement biochemical studies of enzyme complexes.
Overexpression
Overexpression of NSD3 or NSD2 can model oncogenic gain-of-function and test whether elevated H3K36 methylation drives cancer phenotypes. These models are useful for preclinical evaluation of epigenetic inhibitors.
How EDITGENE Supports histone H3K36 methyltransferase activity Research
Researchers studying histone H3K36 methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as cancer cell proliferation, chondrocyte differentiation, or enhancer regulation. Generating precise genetic models is a critical step in this process, and CRISPR-based approaches provide the necessary specificity and flexibility.
Contact EDITGENE today to design your custom CRISPR model for histone H3K36 methyltransferase activity research.
Frequently Asked Questions About histone H3K36 methyltransferase activity
What is histone H3K36 methyltransferase activity?
It is the enzymatic activity (GO:0046975) that transfers a methyl group from S-adenosyl-L-methionine to lysine 36 of histone H3, producing S-adenosyl-L-homocysteine and methylated histone H3.
What genes are involved in histone H3K36 methyltransferase activity?
Key genes include SETD2, NSD1, NSD2, NSD3, and ASH1L, which encode SET-domain enzymes that methylate H3K36.
What is the difference between H3K36me1, H3K36me2, and H3K36me3?
These are mono-, di-, and trimethylated forms of lysine 36 on histone H3, generated by different enzymes and associated with distinct chromatin contexts.
How is histone H3K36 methyltransferase activity linked to cancer?
Elevated NSD3 activity drives squamous cell lung cancer, NSD2 dimethylation promotes lung adenocarcinoma, and SETD2 mutations can reduce H3K36 trimethylation in leukemia.
What diseases are associated with NSD1 mutations?
NSD1 is the Sotos syndrome gene and also protects against osteoarthritis by regulating chondrocyte differentiation and cartilage homeostasis.
How can CRISPR be used to study H3K36 methyltransferases?
CRISPR knockout, point-mutation knock-in, and overexpression models allow causal testing of genes like SETD2, NSD1, NSD2, and NSD3 in disease-relevant cells.
What methods measure H3K36 methylation?
ChIP-seq, Western blot, and mass spectrometry-based assays are commonly used to quantify H3K36 methylation states and enzyme activity.
Is histone H3K36 methyltransferase activity a therapeutic target?
Epigenetic therapies targeting histone lysine methylation are under investigation, but complex mechanisms and clinical challenges remain.
What regulates the activity of H3K36 methyltransferases?
Accessory proteins such as Caf1 can regulate Ash1 activity by sensing unmodified histone H3, and disease mutations can directly impair catalysis.
Where can I get CRISPR models for H3K36 methyltransferase research?
EDITGENE provides knockout, point-mutation, knock-in, overexpression, and library screening services for genes in this pathway.
Conclusion
Histone H3K36 methyltransferase activity (GO:0046975) is a central epigenetic function that controls chromatin states and gene expression programs. Its dysregulation is implicated in cancer, osteoarthritis, and developmental disorders, making it a compelling area for mechanistic and translational research. By combining precise CRISPR models with chromatin, transcriptomic, and proteomic readouts, researchers can dissect how individual enzymes and their regulators contribute to normal physiology and disease. EDITGENE offers a comprehensive suite of services to accelerate this work.
References
- 1. Yuan G et al.. 2021. Elevated NSD3 histone methylation activity drives squamous cell lung cancer.. Nature 590(7846):504-508 PMID: 33536620
- 2. Shao R et al.. 2024. H3K36 methyltransferase NSD1 protects against osteoarthritis through regulating chondrocyte differentiation and cartilage homeostasis.. Cell Death Differ 31(1):106-118 PMID: 38012390
- 3. Gold S et al.. 2024. Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges.. J Clin Invest 134(20) PMID: 39403928
- 4. Yoon E et al.. 2023. Caf1 regulates the histone methyltransferase activity of Ash1 by sensing unmodified histone H3.. Epigenetics Chromatin 16(1):15 PMID: 37118845
- 5. Sengupta D et al.. 2021. NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis.. Mol Cell 81(21):4481-4492.e9 PMID: 34555356
- 6. Michail C et al.. 2026. The SETD2 L1609P mutation found in leukemia disrupts methyltransferase activity and reduces histone H3K36 trimethylation.. J Biol Chem 302(3):111259 PMID: 41654133
- 7. Markert JW et al.. 2025. Structural basis of H3K36 trimethylation by SETD2 during chromatin transcription.. Science 387(6733):528-533 PMID: 39666822
- 8. Sun Z et al.. 2023. Chromatin regulation of transcriptional enhancers and cell fate by the Sotos syndrome gene NSD1.. Mol Cell 83(14):2398-2416.e12 PMID: 37402365
